Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase IIa Study to Evaluate the Efficacy and Safety of Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors

NCT07826195 is registered in ClinicalTrials.gov with Zhejiang Anglikang Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07826195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07826195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase IIa Study to Evaluate the Efficacy and Safety of Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors
Lead sponsor
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
April 30, 2028
Enrollment
174 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastrointestinal tumors